Sign in
CompletedPhase 4

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
33 people enrolled
Started
1 Sept 2020
Ended
22 Jan 2026
Type of study
Interventional
Treatments tested
  • Flumist Quadrivalent Nasal Product
Record updated
25 September 2026

Who can take part

Age
18 years to 49 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • ages 18-49 years old,
  • not yet received influenza vaccine for 2019-2020, and
  • capable of giving signed informed consent

Who cannot take part

  • prior adverse reaction to influenza vaccine,
  • Immunocompromising condition (e.g. HIV/AIDS, chemotherapy, immune suppressing medications),
  • asthma, chronic lung/liver/kidney /neurologic/hematologic/metabolic disorders,cardiovascular disease (excluding isolated hypertension), diabetes mellitus, disease, congestive heart failure,
  • current or recent (within the past month) upper/lower respiratory tract infection, chronic sinusitis/nasal allergies requiring frequent or daily therapy (including topical corticosteroids),
  • history of Guillain-Barre syndrome,
  • egg allergy,
  • active smoking within past 6 months,
  • pregnancy,
  • close contact with an individual with severe immunodeficiency/immunosuppression

Where in United States

  • UAB Lung Health CenterBirmingham, United States

About the trial

What the trial wants to find out

The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)

The group in the trial

  • open labelOther group

    FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer

    Treatment: Flumist Quadrivalent Nasal Product

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
25 September 2026